Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks

NCT00147498 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

264

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: CP-690,550
DRUG: CP-690,550
DRUG: CP-690,550
OTHER: Placebo

Sponsor

Pfizer